• 1
    National Institutes of Health. The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure. NIH Publication 1995; 95 1088: 1 48.
  • 2
    Pahor M, Guralnik J, Corti MC, Foley D, Carbonin P, Havlik R. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191 7.
  • 3
    Furberg C, Psaty B, Meyer J. . Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326 31.
  • 4
    Burnier M & Brunner H. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992; 13 (Suppl. G): 28 33.
  • 5
    Hollenberg N. Strategies in antihypertensive therapy: implications of the kidney. Am J Med 1986; 81 (6A): 15 9.
  • 6
    Pedrinelli R, Fouad F, Tarazi R, Bravo E, Textor S. Nitrendipine, a calcium-entry blocker. Renal and humoral effects in human arterial hypertension. Arch Intern Med 1986; 146: 62 5.
  • 7
    Saito I, Takeshita E, Saruta T, Nagano S, Sekihara T. Effect of a calcium entry blocker on blood pressure, plasma renin activity, aldosterone and catecholamines in normotensive subjects. Clin Endocrinol 1986; 24: 565 70.
  • 8
    Katzman P, Hulthen U, Hokfelt B. The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. Brit J Clin Pharmacol 1986; 21: 633 40.
  • 9
    Resnick L, Nicholson J, Laragh J. Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension 1987; 10: 254 8.
  • 10
    Krishna G, Riley LJ, Deuter G, Kapoor S, Narins R. Natriuretic effect of calcium-channel blockers in hypertensives. Am J Kid Dis 1991; 18: 566 72.
  • 11
    Colantonio D, Casale R, Desiati P, Giandomenico G, Bucci V, Pasqualetti P. Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. J Clin Pharmacol 1991; 31: 238 42.
  • 12
    Cappuccio F, Markandu N, Sagnella G, Singer D, Buckley M, Miller M et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991; 5: 115 9.
  • 13
    Packer M, Lee W, Kessler P, Gottlieb S, Bernstein J, Kukin M. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987; 75 (Suppl.): IV80 92.
  • 14
    Rouleau J, DeChamplain J, Klein M, Bichet D, Moye L, Packer M, Dagenais G, Sussex B et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 390 98.
  • 15
    Dickstein K, Larsen A, Bonarje V, Thoresen M, Aarsland T, Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol 1995; 76: 679 83.
  • 16
    Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232 7.
  • 17
    Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730 36.
  • 18
    Keil U, Stieber J, Döring A, Härtel U, Filipatrik B, Hense HW. The cardiovascular risk profile in the study area Augsburg: results from the first MONICA survey 1984/1985. Acta Med Scand 1988; 728 (Suppl.): 119 28.
  • 19
    Schunkert H, Danser AHJ, Hense H-W, Derkx FHM, Kürzinger S, Riegger G. Effects of estrogen replacement therapy on the renin angiotensin system in postmenopausal women. Circulation 1997; 95: 39 45.
  • 20
    Schunkert H, Hense H, Gimenez-Roqueplo A, Stieber J, Keil U, Riegger G et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997; 29: 628 33.
  • 21
    Schunkert H, Hense H-W, Danser AHJ, Muscholl M, Luchner A, Riegger A. Association between circulating components of the renin angiotensin aldosterone system and left ventricular mass. Br Heart J 1997; 77: 24 31.
  • 22
    Devereux RB, Koren MJ, DeSimone P, Okin N, Klingfield P. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993; 14 (Suppl. D): 8 15.
  • 23
    Derkx FHM, DeBruin RJA, Gool JM, Gv Hoek MJ, Cv Beerendonk CCM, Rosmalem FMA et al. Clinical validation of monoclonal renin antibody sandwich assays of renin and prorenin. Clin Chem 1996; 42: 1051 63.
  • 24
    Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin S, Talness C et al. Evidence for tissue specific activation of renal angiotensinogen mRNA expression in chronic stable heart failure. J Clin Invest 1992; 90: 1523 9.
  • 25
    Schunkert H, Ingelfinger J, Hirsch AT, Pinto Y, Jacob H, Dzau V. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993; 72: 312 8.
  • 26
    Schunkert H, Hense HW, Holmer SR, Stender K, Perz S, Keil U et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634 8.
  • 27
    Zanchetti A, Stella A, Leonetti G, Morganti A, Terzoli L. Control of renin release: a review of experimental evidence and clinical implications. Am J Cardiol 1976; 37: 675 91.
  • 28
    VandenMeiracker A, Manin'tVeld A, Boomsma F, Fischberg D, Molinoff P, Schalekamp M. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 1989; 80: 903 14.
  • 29
    Deray G, Berlin I, Maistre G, Martine F, Legrand S, Carayon A et al. Beta-adrenoceptor blockade potentiates exercise-induced release of atrial natriuretic peptide. Eur J Clin Pharmacol 1990; 38: 363 6.
  • 30
    McKenna F & Davison A. Renin and beta-blockade: prorenin and aldosterone may explain the controversy. Clin Nephrol 1986; 25: 149 54.
  • 31
    Dupont A, VanderNiepen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt A et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 (Suppl. 11): S130 6.
  • 32
    Johnston C, Millar J, McGrath B, Matthews P. Long-term effects of captopril (SQ14, 225) on blood-pressure and hormone levels in essential hypertension. Lancet 1979; 2 (8141): 493 6.
  • 33
    Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol 1993; 71: 34A–39A (Suppl.).
  • 34
    Pitt B. ‘Escape’ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor implications for therapy. Cardiovascular Drugs Ther 1995; 9: 145 9.
  • 35
    Holmer S, Hense H-W, Danser AHJ, Schunkert H. Beta-adrenergic control of renin stimulation by ACE inhibitors and diuretics. Circulation 1996; 94 (Suppl. I): 94–5 (abstract).
  • 36
    Gilchrist N, Nicholls M, Ewer T, Livesey J, Sainsbury R. A comparison of long acting nifedipine and enalapril in elderly hypertensives: a randomised, single-blind, cross-over study. J Hum Hypertens 1988; 2: 33 9.
  • 37
    Weidmann P, DeMyttenaere-Bursztein S, Maxwell M, DeLima J. Effect on aging on plasma renin and aldosterone in normal man. Kidney Int 1975; 8: 325 33.
  • 38
    Danser AHJ, DeBruin RJA, Derkx FHM, Schalekamp Madh, Riegger GAJ, Schunkert H. Determinants of interindividual prorenin variation in humans. J Hypertens 1996; 14 (Suppl. 1): S4 (abstract).
  • 39
    Ohashi M, Fujio N, Nawata H, Kato K, Ibayashi H, Kangawa K et al. High plasma concentrations of human atrial natriuretic polypeptide in aged men. J Clin Endocrinol Metabol 1987; 64: 81 5.
  • 40
    Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343 6.
  • 41
    De Lignieres BD, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J et al. Biological effects of estradiol-17β in postmenopausal woman: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536 41.
  • 42
    Bell GM, Bernstein R, Laragh JH, Atlas S, James GD, Pecker M, Sealey J. Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes mellitus. Clin Sci 1989; 77: 177 82.
  • 43
    Flickinger A, Burnett J, Turner S. Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clinic Proc 1995; 70: 932 8.